Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-086179 · Präparat HOS-083284
Medicinal Product Interactions – Ritonavir with Protease Inhibitors
Co-administered Dose of Co- Dose of Medicinal Product AUC Cmin
Medicinal Product administered NORVIR Assessed
Medicinal (mg)
Product
(mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7 fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition.
Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with
ritonavir 100 mg once daily in treatment experienced patients. For further information,
physicians should refer to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition.
Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses
higher than 100 mg twice daily have not been studied with darunavir. For further
information, refer to the SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice
daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily
10
have not been studied with fosamprenavir. For further information, physicians should refer
to the SmPC for fosamprenavir.
Indinavir 800 100 q12h Indinavir2 ↑ 178% ND
q12h
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily. In cases of co-administration of
ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as
the risk of nephrolithiasis may be increased.
Nelfinavir 1250 100 q12h Nelfinavir ↑ ND
q12h 20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily.
Tipranavir 500 200 q12h Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition.
Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of
ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter
the efficacy of the combination. For further information, physicians should refer to the
SmPC for tipranavir.
ND: Not determined.
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 03a194213ac89748c50cfb4b51554f8455df8df904ff2077009223828e61e82e · Zeichen 2655–7456 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-086344 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 3c27321459baa7b0705afde806e8b539a0a25a4b47e2383e187fb6fd8f60bfb2 · Zeichen 60628–61278 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086399 · Präparat HOS-083284
Co- Dose of Co- Dose of Medicinal Product AUC Cmin
administered administered NORVIR Assessed
Medicinal Medicinal Product (mg)
Product (mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7
fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical
trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg
once daily in treatment experienced patients. For further information, physicians should refer
to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir
must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than
100 mg twice daily have not been studied with darunavir. For further information, refer to the
SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily
with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily have not
been studied with fosamprenavir. For further information, physicians should refer to the
SmPC for fosamprenavir.
Indinavir 800 q12h 100 q12h Indinavir2 ↑ 178% ND
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg
twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of
nephrolithiasis may be increased.
Nelfinavir 1250 q12h 100 q12h Nelfinavir ↑ ND
20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily.
Tipranavir 500 q12h 200 Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir
must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less
than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of
the combination. For further information, physicians should refer to the SmPC for tipranavir.
ND: Not determined.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d5308747ba178c6ebd0e34322c465d7122d5458d70aff134d17f324382a8fc16 · Zeichen 2732–7211 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086400 · Präparat HOS-083284
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 71fe7e533a1b113d7cbf463366af463ab42e4213a8966cd09c1bffbe648c857a · Zeichen 7235–7410 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-086497 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 4de66caff969925d9ad024610386f020326d8902794177858246b69263b12d3c · Zeichen 62968–63646 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-088091 · Präparat HOS-083615
9
PIs
Atazanavir/ritonavir Atazanavir/r 300/100 mg: It is not recommended to co-
300/100 mg QD Atazanavir/r AUC 0.58 administer atazanavir/ritonavir and
400/100 mg QD (0.48-0.71) Viramune (see section 4.4).
Atazanavir/r Cmin 0.28
(0.20-0.40)
Atazanavir/r Cmax 0.72
(0.60-0.86)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 18bf751163ef37d02d12be099976bc63d94d2a80c8d8555d9538fa6ec8f12ced · Zeichen 5933–6378 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-088092 · Präparat HOS-083615
Atazanavir/r 400/100 mg:
Atazanavir/r AUC 0.81
(0.65-1.02)
Atazanavir/r Cmin 0.41
(0.27-0.60)
Atazanavir/r Cmax 1.02
(0.85-1.24)
(compared to 300/100 mg without
nevirapine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage f67f6bd4fa6677adf3f7d3920bcb768940def170155d8b7f1aed82c7183aa30c · Zeichen 6403–6765 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 34
HOS-088190 · Präparat HOS-083615
PIs
Atazanavir/ritonavir Atazanavir/r 300/100 mg: It is not recommended to co-
300/100 mg QD Atazanavir/r AUC 0.58 administer atazanavir/ritonavir and
400/100 mg QD (0.48-0.71) Viramune (see section 4.4).
Atazanavir/r Cmin 0.28
(0.20-0.40)
Atazanavir/r Cmax 0.72
(0.60-0.86)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 6699c1bb19b1e24e9c6772c4b7525387f199ba89ed39172463d9743761e41ae2 · Zeichen 6102–6544 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 34–35
HOS-088191 · Präparat HOS-083615
Atazanavir/r 400/100 mg:
34
Atazanavir/r AUC 0.81
(0.65-1.02)
Atazanavir/r Cmin 0.41
(0.27-0.60)
Atazanavir/r Cmax 1.02
(0.85-1.24)
(compared to 300/100 mg without
nevirapine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage ca3f42fa4d00954c23c6444a4067759b98669bcc82ef691230c4607d38f4710a · Zeichen 6569–6989 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-088283 · Präparat HOS-083615
59
PIs
Atazanavir/ritonavir Atazanavir/r 300/100 mg: It is not recommended to co-
300/100 mg QD Atazanavir/r AUC 0.58 administer atazanavir/ritonavir and
400/100 mg QD (0.48-0.71) Viramune (see section 4.4).
Atazanavir/r Cmin 0.28
(0.20-0.40)
Atazanavir/r Cmax 0.72
(0.60-0.86)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 500effe99f6c97ba046c992bd79595236a77bf2c225135bfdd1ee71211982714 · Zeichen 6252–6698 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 60
HOS-088284 · Präparat HOS-083615
Atazanavir/r 400/100 mg:
Atazanavir/r AUC 0.81
(0.65-1.02)
Atazanavir/r Cmin 0.41
(0.27-0.60)
Atazanavir/r Cmax 1.02
(0.85-1.24)
(compared to 300/100 mg without
nevirapine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage f67f6bd4fa6677adf3f7d3920bcb768940def170155d8b7f1aed82c7183aa30c · Zeichen 6723–7085 im Abschnitt
Gegenanzeigen · Pegasys
Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe · Abschnitt 4.3 · PDF-Seite 11
HOS-109794 · Präparat HOS-093265
• Hypersensitivity to the active substance, to alfa interferons, or to any of the excipients listed in
section 6.1
• History or presence of autoimmune diseases
• Pre-existing thyroid disease unless it can be controlled with conventional treatment
• Severe hepatic dysfunction or decompensated cirrhosis of the liver
• A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac
disease in the previous six months (see section 4.4)
• HIV-HCV patients with cirrhosis and a Child-Pugh score ≥ 6, except if only due to indirect
hyperbilirubinemia caused by medicinal products such as atazanavir and indinavir
• Combination with telbivudine (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) telbivudine (HOS-088129)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 1f98180aff26f1ffe55dad933e2b403ec59d2525331f1335f064e3709361733f · Zeichen 0–772 im Abschnitt
Gegenanzeigen · Pegasys
Pegasys 180 micrograms solution for injection · Abschnitt 4.3 · PDF-Seite 49
HOS-109862 · Präparat HOS-093265
• Hypersensitivity to the active substance, to alfa interferons, or to any of the excipients listed in
section 6.1
• Autoimmune hepatitis
• Severe hepatic dysfunction or decompensated cirrhosis of the liver
• A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac
disease in the previous six months (see section 4.4)
• HIV-HCV patients with cirrhosis and a Child-Pugh score ≥ 6, except if only due to indirect
hyperbilirubinemia caused by medicinal products such as atazanavir and indinavir
• Combination with telbivudine (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) telbivudine (HOS-088129)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 078594fce208dea907bbbb464ce7025107acdc08b854b63c0bb900d9f2ae8462 · Zeichen 0–655 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-110490 · Präparat HOS-093385
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
ANTI-INFECTIVES
Antiretrovirals
Protease inhibitors
Atazanavir/Ritonavir Atazanavir: No dose adjustment is
(300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased
Cmax: ↓ 28% exposure of tenofovir could
Cmin: ↓ 26% potentiate tenofovir-associated
Tenofovir: adverse events, including renal
AUC: ↑ 37% disorders. Renal function should
Cmax: ↑ 34% be closely monitored
Cmin: ↑ 29% (see section 4.4).
Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is
(400 b.i.d./100 b.i.d.) No significant effect on recommended. The increased
lopinavir/ritonavir PK exposure of tenofovir could
parameters. potentiate tenofovir-associated
Tenofovir: adverse events, including renal
AUC: ↑ 32% disorders. Renal function should
Cmax: ↔ be closely monitored
Cmin: ↑ 51% (see section 4.4).
Darunavir/Ritonavir Darunavir: No dose adjustment is
(300/100 b.i.d.) No significant effect on recommended. The increased
darunavir/ritonavir PK exposure of tenofovir could
parameters. potentiate tenofovir-associated
Tenofovir: adverse events, including renal
AUC: ↑ 22% disorders. Renal function should
Cmin: ↑ 37% be closely monitored
(see section 4.4).
NRTIs
Didanosine Co-administration of tenofovir Co-administration of tenofovir
disoproxil and didanosine results disoproxil and didanosine is not
in a 40-60% increase in systemic recommended (see section 4.4).
exposure to didanosine.
Increased systemic exposure to
didanosine may increase
didanosine related adverse
reactions. Rarely, pancreatitis and
lactic acidosis, sometimes fatal,
have been reported.
Co-administration of tenofovir
disoproxil and didanosine at a
dose of 400 mg daily has been
associated with a significant
decrease in CD4 cell count,
possibly due to an intracellular
interaction increasing
phosphorylated (i.e. active)
didanosine. A decreased dosage of
250 mg didanosine
co-administered with tenofovir
disoproxil therapy has been
associated with reports of high
rates of virological failure within
several tested combinations for the
treatment of HIV-1 infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) didanosine (HOS-085836) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 2da8a9413a0cdf6c2adfbb5e8a3514645ef92df343ae795985c6e470290e6c16 · Zeichen 1811–6985 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-110492 · Präparat HOS-093385
9
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Adefovir dipivoxil AUC: ↔ Tenofovir disoproxil should not be
Cmax: ↔ administered concurrently with
adefovir dipivoxil
(see section 4.4).
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations
(90 mg/400 mg q.d.) + AUC: ↑ 96% of tenofovir resulting from
Atazanavir/Ritonavir Cmax: ↑ 68% co-administration of tenofovir
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% disoproxil, ledipasvir/sofosbuvir
Emtricitabine/Tenofovir disoproxil and atazanavir/ritonavir may
(200 mg/245 mg q.d.)1 Sofosbuvir: increase adverse reactions related
AUC: ↔ to tenofovir disoproxil, including
Cmax: ↔ renal disorders. The safety of
tenofovir disoproxil when used
GS-3310072: with ledipasvir/sofosbuvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↔ ritonavir or cobicistat) has not
Cmin: ↑ 42% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 824f9677703ef0bd8736160366b3629ad69b12899569fa4edf1bdab9fd603c0c · Zeichen 7039–9028 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110496 · Präparat HOS-093385
Atazanavir: The combination should be used
AUC: ↔ with caution with frequent renal
Cmax: ↔ monitoring, if other alternatives
Cmin: ↑ 63% are not available (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 04fd0cdc7ef8d2df133646692be1fa366c35e75e4adec569de19cc4b924d841d · Zeichen 9067–9436 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-110514 · Präparat HOS-093385
13
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations
(400 mg/100 mg q.d.) + AUC: ↔ of tenofovir resulting from
Atazanavir/Ritonavir Cmax: ↔ co-administration of tenofovir
(300 mg q.d./100 mg q.d.) + disoproxil, sofosbuvir/velpatasvir
Emtricitabine/Tenofovir disoproxil GS-3310072: and atazanavir/ritonavir may
(200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related
Cmax: ↔ to tenofovir disoproxil, including
Cmin: ↑ 42% renal disorders. The safety of
tenofovir disoproxil when used
Velpatasvir: with sofosbuvir/velpatasvir and a
AUC: ↑ 142% pharmacokinetic enhancer (e.g.
Cmax: ↑ 55% ritonavir or cobicistat) has not
Cmin: ↑ 301% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage a352840ea53b0c7aa2c2c1477faa3502b999395202d25ef8a0192525e4dfa26d · Zeichen 18217–19800 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-110515 · Präparat HOS-093385
Atazanavir: The combination should be used
AUC: ↔ with caution with frequent renal
Cmax: ↔ monitoring (see section 4.4).
Cmin: ↑ 39%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage c08e096c4f293f53390832606ae89170f54e5a5784e9ca3fb6aa89ef62ba0442 · Zeichen 19839–20148 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-110592 · Präparat HOS-093385
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
ANTI-INFECTIVES
Antiretrovirals
Protease inhibitors
Atazanavir/Ritonavir Atazanavir: No dose adjustment is
(300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased
Cmax: ↓ 28% exposure of tenofovir could
Cmin: ↓ 26% potentiate tenofovir-
Tenofovir: associated adverse events,
AUC: ↑ 37% including renal disorders.
Cmax: ↑ 34% Renal function should be
Cmin: ↑ 29% closely monitored
(see section 4.4).
Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is
(400 b.i.d./100 b.i.d.) No significant effect on lopinavir/ritonavir recommended. The increased
PK parameters. exposure of tenofovir could
Tenofovir: potentiate tenofovir-
AUC: ↑ 32% associated adverse events,
Cmax: ↔ including renal disorders.
Cmin: ↑ 51% Renal function should be
closely monitored
(see section 4.4).
Darunavir/Ritonavir Darunavir: No dose adjustment is
(300/100 b.i.d.) No significant effect on darunavir/ritonavir recommended. The increased
PK parameters. exposure of tenofovir could
Tenofovir: potentiate tenofovir-
AUC: ↑ 22% associated adverse events,
Cmin: ↑ 37% including renal disorders.
Renal function should be
closely monitored
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 97402b6653ccc27600d152ec08f35f2adaabc6d7df63e20237baf32481f6489e · Zeichen 1810–4982 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-110596 · Präparat HOS-093385
49
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↑ 96% concentrations of tenofovir
Atazanavir/Ritonavir Cmax: ↑ 68% resulting from
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↔ atazanavir/ritonavir may
Cmax: ↔ increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↑ 42% ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Atazanavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↑ 63% The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 45%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 6c5102c58c0a5342683c6dffc2f5f0ed4e9e471a1d14b33916f9bf2e1e1b3bb9 · Zeichen 8813–11440 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.